August 27, 2018 / 8:42 PM / 2 months ago

U.S. FDA declines to approve Akcea/Ionis genetic disease drug

Aug 27 (Reuters) - The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the blood.

An advisory committee to the health regulator voted 12-8 in favor of the drug in a meeting held in May. (Reporting by Aakash Jagadeesh Babu, Tamara Mathias and Ankit Ajmera in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below